Anika Therapeutics (ANIK) Goodwill (2010 - 2026)

Anika Therapeutics (ANIK) has reported Goodwill for 17 consecutive years, with $7.8 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Goodwill fell 2.87% year-over-year to $7.8 million in Q2 2026; TTM through Jun 2026 was $7.8 million, a 2.87% decrease from a year earlier, with the FY2025 full-year figure at $8.1 million, up 13.04% from the prior year.
• Goodwill was $7.8 million for Q2 2026 at Anika Therapeutics, down from $7.9 million in the prior quarter.
• Over five years, Goodwill peaked at $8.1 million in Q2 2025 and troughed at $6.7 million in Q3 2022.
• A 5-year average of $7.5 million and a median of $7.5 million in 2023 frame the typical range for Goodwill.
• Across the five-year window, Goodwill retreated 15.46% in 2022 and advanced 13.04% in 2025, its largest moves.
• Over 5 years, Goodwill stood at $7.3 million in 2022, then rose by 3.16% to $7.6 million in 2023, then fell by 5.89% to $7.1 million in 2024, then gained by 13.04% to $8.1 million in 2025, then retreated by 2.84% to $7.8 million in 2026.
• The last three Goodwill figures came in at $7.8 million (Q2 2026), $7.9 million (Q1 2026), and $8.1 million (Q4 2025), per Business Quant data.